The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis

The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis

Abstract Background The 2022 Canadian Cardiovascular Society (CCS) cardiorenal guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) use. Since then, additional trials of relevance for SGLT2i have been...

Full description

Bibliographic Details
Main Authors: Muhammad Usman Ali, G. B. John Mancini, Donna Fitzpatrick-Lewis, Kim A. Connelly, Eileen O’Meara, Shelley Zieroth, Diana Sherifali
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Cardiovascular Diabetology
Subjects:
Meta-analysis
Sodium-glucose co-transporter 2 inhibitors
Glucagon-like peptide-1 receptor agonists
Cardiorenal outcomes
Online Access:https://doi.org/10.1186/s12933-024-02154-w

Internet

https://doi.org/10.1186/s12933-024-02154-w

Similar Items